HAVCR2 and neoplasm: TIM-3 has emerged as a promising target for cancer immunotherapy, with studies demonstrating that the in vivo blockade of TIM-3 alongside other checkpoint inhibitors improves antitumor immunity and inhibits tumor development in various preclinical tumor models [19].